BridgeMD
New treatment option for Telomere Length
Official title Avocado Consumption and Cellular Aging in Breast Cancer Survivors
ClinicalTrials.gov ID: NCT07097155
What this study is testing
- What it's testing
- Women with breast cancer are at increased risk of comorbidities and premature mortality, potentially due to accelerated biological aging. Telomere attrition has been proposed as a biomarker of this process, which could be mitigated through interventions targeting behavioral factors such as diet.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 40 to 65, women only
You may be able to join if
- Women diagnosed with primary breast cancer in stages I, II or III;
- 40-65 years old at screening;
- Cancer treatment (radiotherapy and chemotherapy) completed ≥ 6 months but not more than 10 years at the time of recruitment;
- Currently consuming less than 2 avocados per week;
- Signed the informed consent letter.
You likely can't join if
- Metastasis;
- Ductal carcinoma or lobular carcinoma in situ;
- Breast cancer recurrence;
- Cancer diagnosis other than breast cancer or non-melanoma skin cancer;
- Body mass index ≥40kg/m2;
- Currently pregnant or breastfeeding, or planning pregnancy in the following 6 months;
See the full eligibility criteria
- Women diagnosed with primary breast cancer in stages I, II or III;
- 40-65 years old at screening;
- Cancer treatment (radiotherapy and chemotherapy) completed ≥ 6 months but not more than 10 years at the time of recruitment;
- Currently consuming less than 2 avocados per week;
- Signed the informed consent letter.
- Metastasis;
- Ductal carcinoma or lobular carcinoma in situ;
- Breast cancer recurrence;
- Cancer diagnosis other than breast cancer or non-melanoma skin cancer;
- Body mass index ≥40kg/m2;
- Currently pregnant or breastfeeding, or planning pregnancy in the following 6 months;
- Allergy to latex;
- Unwilling to consume avocado;
- Immunodeficiency or HIV-positive status;
- Alcohol abuse (\>50g/day);
- Unstable use of plant sterols, mineral supplements, use of fibre supplements, fish oil, or antioxidants in the 4 weeks prior to enrolment, or plans to change this during the study;
- Currently participating in any other assigned by chance controlled trial;
- Difficulty or impossibility of an adequate follow-up;
- Inability or unwillingness to give written informed consent or to communicate with study personnel, or illiteracy;
- Patients with an acute infection or inflammation (e.g., pneumonia) will be allowed to participate in the study 3 months after recovery.
The study team makes the final eligibility decision.
Where it's taking place
- Reus, Tarragona, Spain
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 40 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Reus, Tarragona, Spain. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.